Debiopharm launches competition for single dose COVID-19 mRNA vaccine

By The Science Advisory Board staff writers

April 20, 2021 -- Debiopharm has announced a global challenge in an effort to develop a single-dose messenger RNA (mRNA) COVID-19 vaccine.

Launched within the InnoCentive crowdsourcing innovation platform, the challenge seeks to identify a single-source mRNA vaccine that can provide the same level of COVID-19 protection as approved multidose vaccines, according to the company. The competition includes participants from various backgrounds, including science, engineering, and technology.

To participate, a written proposal must be submitted directly via the InnoCentive platform by the end of May. The winning proposal will be awarded a monetary prize and be acquired by Debiopharm for further development.

More information can be found on the challenge's website.

Debiopharm, Genome & Company collaborate on antibody-drug conjugates
Debiopharm and Genome & Company announced a plan to collaborate on developing antibody-drug conjugate oncology therapies.
Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter